Eric Van Cutsem

Research interests

Publications

• Zolbetuximab plus mFOLFOX6 in patients with CLDN18.2-positive, HER2-negative, untreated, locally advanced unresectable or metastatic gastric or gastro-oesophageal junction adenocarcinoma (SPOTLIGHT): a multicentre, randomised, double-blind, phase 3 trial

  The Lancet · 2023 · https://doi.org/10.1016/s0140-6736(23)00620-7

• Adjuvant Nivolumab in Resected Esophageal or Gastroesophageal Junction Cancer

  New England Journal of Medicine · 2021 · https://doi.org/10.1056/nejmoa2032125

• The KEYNOTE-811 trial of dual PD-1 and HER2 blockade in HER2-positive gastric cancer

  Nature · 2021 · https://doi.org/10.1038/s41586-021-04161-3

• Pemigatinib for previously treated, locally advanced or metastatic cholangiocarcinoma: a multicentre, open-label, phase 2 study

  The Lancet Oncology · 2020 · 10.1016/s1470-2045(20)30109-1

• Efficacy and Safety of Pembrolizumab or Pembrolizumab Plus Chemotherapy vs Chemotherapy Alone for Patients With First-line, Advanced Gastric Cancer

  JAMA Oncology · 2020 · https://doi.org/10.1001/jamaoncol.2020.3370

• Pembrolizumab in Microsatellite-Instability–High Advanced Colorectal Cancer

  New England Journal of Medicine · 2020 · https://doi.org/10.1056/nejmoa2017699

• Phase II Open-Label Study of Pembrolizumab in Treatment-Refractory, Microsatellite Instability–High/Mismatch Repair–Deficient Metastatic Colorectal Cancer: KEYNOTE-164

  Journal of Clinical Oncology · 2019 · 10.1200/jco.19.02107

• Maintenance Olaparib for Germline BRCA -Mutated Metastatic Pancreatic Cancer

  New England Journal of Medicine · 2019 · 10.1056/nejmoa1903387

• Encorafenib, Binimetinib, and Cetuximab in BRAF V600E–Mutated Colorectal Cancer

  New England Journal of Medicine · 2019 · 10.1056/nejmoa1908075

• Durable Clinical Benefit With Nivolumab Plus Ipilimumab in DNA Mismatch Repair–Deficient/Microsatellite Instability–High Metastatic Colorectal Cancer

  Journal of Clinical Oncology · 2018 · 10.1200/jco.2017.76.9901

• Prognostic and predictive value of primary tumour side in patients with RAS wild-type metastatic colorectal cancer treated with chemotherapy and EGFR directed antibodies in six randomized trials

  Annals of Oncology · 2017 · 10.1093/annonc/mdx175

• Phase 3 Trial of 177 Lu-Dotatate for Midgut Neuroendocrine Tumors

  New England Journal of Medicine · 2017 · 10.1056/nejmoa1607427

• Prognostic and Predictive Relevance of Primary Tumor Location in Patients With RAS Wild-Type Metastatic Colorectal Cancer

  JAMA Oncology · 2016 · 10.1001/jamaoncol.2016.3797

• ESMO consensus guidelines for the management of patients with metastatic colorectal cancer

  Annals of Oncology · 2016 · https://doi.org/10.1093/annonc/mdw235

• Gastric cancer

  The Lancet · 2016 · 10.1016/s0140-6736(16)30354-3

• Ramucirumab versus placebo in combination with second-line FOLFIRI in patients with metastatic colorectal carcinoma that progressed during or after first-line therapy with bevacizumab, oxaliplatin, and a fluoropyrimidine (RAISE): a randomised, double-blind, multicentre, phase 3 study

  The Lancet Oncology · 2015 · 10.1016/s1470-2045(15)70127-0

• Randomized Trial of TAS-102 for Refractory Metastatic Colorectal Cancer

  New England Journal of Medicine · 2015 · 10.1056/nejmoa1414325

• Ramucirumab plus paclitaxel versus placebo plus paclitaxel in patients with previously treated advanced gastric or gastro-oesophageal junction adenocarcinoma (RAINBOW): a double-blind, randomised phase 3 trial

  The Lancet Oncology · 2014 · 10.1016/s1470-2045(14)70420-6

• Increased Survival in Pancreatic Cancer with nab-Paclitaxel plus Gemcitabine

  New England Journal of Medicine · 2013 · https://doi.org/10.1056/nejmoa1304369

• Regorafenib monotherapy for previously treated metastatic colorectal cancer (CORRECT): an international, multicentre, randomised, placebo-controlled, phase 3 trial

  The Lancet · 2012 · 10.1016/s0140-6736(12)61900-x

• Addition of Aflibercept to Fluorouracil, Leucovorin, and Irinotecan Improves Survival in a Phase III Randomized Trial in Patients With Metastatic Colorectal Cancer Previously Treated With an Oxaliplatin-Based Regimen

  Journal of Clinical Oncology · 2012 · 10.1200/jco.2012.42.8201

• ESMO Consensus Guidelines for management of patients with colon and rectal cancer. A personalized approach to clinical decision making

  Annals of Oncology · 2012 · 10.1093/annonc/mds236

• Cetuximab Plus Irinotecan, Fluorouracil, and Leucovorin As First-Line Treatment for Metastatic Colorectal Cancer: Updated Analysis of Overall Survival According to Tumor KRAS and BRAF Mutation Status

  Journal of Clinical Oncology · 2011 · 10.1200/jco.2010.33.5091

• Everolimus for Advanced Pancreatic Neuroendocrine Tumors

  New England Journal of Medicine · 2011 · 10.1056/nejmoa1009290

• Sunitinib Malate for the Treatment of Pancreatic Neuroendocrine Tumors

  New England Journal of Medicine · 2011 · 10.1056/nejmoa1003825

• Capecitabine Plus Oxaliplatin Compared With Fluorouracil and Folinic Acid As Adjuvant Therapy for Stage III Colon Cancer

  Journal of Clinical Oncology · 2011 · 10.1200/jco.2010.33.6297

• Effects of KRAS, BRAF, NRAS, and PIK3CA mutations on the efficacy of cetuximab plus chemotherapy in chemotherapy-refractory metastatic colorectal cancer: a retrospective consortium analysis

  The Lancet Oncology · 2010 · 10.1016/s1470-2045(10)70130-3

• Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial

  The Lancet · 2010 · https://doi.org/10.1016/s0140-6736(10)61121-x

• Prognostic Role of KRAS and BRAF in Stage II and III Resected Colon Cancer: Results of the Translational Study on the PETACC-3, EORTC 40993, SAKK 60-00 Trial

  Journal of Clinical Oncology · 2009 · 10.1200/jco.2009.23.3452

• Cetuximab and Chemotherapy as Initial Treatment for Metastatic Colorectal Cancer

  New England Journal of Medicine · 2009 · https://doi.org/10.1056/nejmoa0805019

• Wild-Type KRAS Is Required for Panitumumab Efficacy in Patients With Metastatic Colorectal Cancer

  Journal of Clinical Oncology · 2008 · 10.1200/jco.2007.14.7116

• Perioperative chemotherapy with FOLFOX4 and surgery versus surgery alone for resectable liver metastases from colorectal cancer (EORTC Intergroup trial 40983): a randomised controlled trial

  The Lancet · 2008 · 10.1016/s0140-6736(08)60455-9

• Open-Label Phase III Trial of Panitumumab Plus Best Supportive Care Compared With Best Supportive Care Alone in Patients With Chemotherapy-Refractory Metastatic Colorectal Cancer

  Journal of Clinical Oncology · 2007 · 10.1200/jco.2006.08.1620

• Phase III Study of Docetaxel and Cisplatin Plus Fluorouracil Compared With Cisplatin and Fluorouracil As First-Line Therapy for Advanced Gastric Cancer: A Report of the V325 Study Group

  Journal of Clinical Oncology · 2006 · 10.1200/jco.2006.06.8429

• Cetuximab Monotherapy and Cetuximab plus Irinotecan in Irinotecan-Refractory Metastatic Colorectal Cancer

  New England Journal of Medicine · 2004 · https://doi.org/10.1056/nejmoa033025

• American Society of Clinical Oncology Recommendations on Adjuvant Chemotherapy for Stage II Colon Cancer

  Journal of Clinical Oncology · 2004 · 10.1200/jco.2004.05.063

Current projects

No projects listed.